Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Don't be so paranoid. They only list Jack Weinstein and Ram Selvaraju. Probably a poor decision, but that doesn't mean they are lying.
Javitt is not the only one not listed. Gilles Della Corte, Chief Medical Officer, Jeremy Meinen, VP Finance and Administration and Peter Egon de Svastich. Director, are also not listed.
NOT LISTED DOES NOT MEAN THEY DO NOT HOLD THOSE POSITIONS AS LISTED IN MY WSJ LINK
Javitt is clearly listed as Vice Chairman on this link. So please keep your promise and STOP POSTING:
https://www.wsj.com/market-data/quotes/CH/XSWX/RLF/company-people/executive-profile/186895305
NeuroRx expanded access request page for aviptadil:
https://www.neurorxpharma.com/our-services/usa-licensed-physicians/
I don't see any reason why aviptadil nasal spray won't prevent Covid 19, if used daily as prophylaxis.
Could you please tell me more about those five derivatives? Is there a reference?
People are still confused about this. RLF-100 is VIP.
Different applications of VIP will require different formulations. I hope Relief/NeuroRx comes up with all the formulations, but that is probably unrealistic. Right now they only have the IV and inhaler formulations as far as I know.
I would think dex would be given to both treatment and control arms. It cannot be denied to control patients because it is part of standard treatment now. So dex effect would cancel out and only RLF-100 effect will show up.
My two cents.
There is no evidence that subcutaneous drugs are less effective in comatose patients, eg, insulin, etc. Good theory though!
I think the simple reason for the lack of effectiveness of the PhaseBio version of VIP for lung disease is because its linkage with ELP fusion protein makes it selectively active at VPAC2, whereas VIP by itself is active at both VPAC1 and VPAC2 receptors. The linkage with ELP fusion protein changes its activity, even though it also VIP.
From Wikipedia:
VPAC1 is expressed in the brain (cerebral cortex, hippocampus, amygdala), lung, prostate, peripheral blood leukocytes, liver, small intestine, heart, spleen, placenta, kidney, thymus and testis.
VAPC2 is expressed in the uterus, prostate, smooth muscle of the gastrointestinal tract, seminal vesicles and skin, blood vessels and thymus. VVAPC2 is also expressed in the cerebellum
I'm not sure what you mean. The image shows the process of oxidative phosphorylation. What does that have to do with VIP improving pO2?
Can you please provide a reference?
I had no trouble
Herbals and supplements can be sold without claims. Any claims have to go through FDA approval process.
One thing I noticed is the latest publication and grant date for this group of 86 is 2013. Is there a more current list?
Based on their mathematical search algorithm as described in the presentation booklet, they should have hundreds of candidates by now.
If you scroll further to the right, you will see the "status", which is abandoned, withdrawn, or expired for a lot of them. But the Relief web site indicates they have products available for licensing and development. I assume at least some of them are listed in this document. They do have a contact link for further inquiries.
This jives with the info from RLF web site I posted previously. From this statement it looks like many, if not all, patents are current:
Over the years, Relief Therapeutics has obtained a large number of patented indications for various peptides and proteins of natural origin. Although Relief is conscious that these experimental medicinal products might be beneficial to the patients, its limited resources prevent Relief from developing them further. These programs can be out-licensed to interested companies or organizations. Do not hesitate to contact us.
So RLF may turn out to be a peptides powerhouse!
Plus, it looks like they have many other peptides on the back burner for future development. We are just waiting for aviptadil to take off first. The rest will follow in time. Even aviptadil is looking like it has multiple potential indications.
I'm hopeful for a very big ROI in the next 3-5 years. Maybe they'll be bought out before that. Let's see how it pans out.
All these are good questions. I suppose we have to wait and see what kinds of different formulations they have. However, by natural agonist, I take them to mean VIP. I still think aviptadil is just the synthetic form of VIP. They are extolling the benefits of a natural agonist because it acts on more receptors. It might be a good thing in this case because VIP has so few side effects. Usually, action on more receptors usually means more undesired side effects, that's why we see so many drug classes where the first to appear are usually "dirty" because they act on multiple receptors. Later, they develop selective agents with more focused action on certain receptors to maximize benefit and minimize side effects.
So it looks like they have two different technologies; first, to synthesize VIP, as opposed to extracting it from natural sources; second, different formulations for different applications.
The RLF web site doesn't mention any extra agonists added to aviptadil.
VIP and aviptadil have the same mechanism of action because they are identical.
https://relieftherapeutics.com/compounds-2/
Aviptadil is patented because of its formulation, ie, substances added to VIP to enhance a particular delivery method, eg, inhaler or IV in this case. The half life does not change in either case as far as I know. As it is, 2 minutes is long enough for it to attach to the appropriate receptors and do its thing.
The only form of VIP with a longer half-life that I know of is the subcutaneous form developed by Phase Bio, which actually attaches an ELP fusion protein to one end of VIP to prolong the half life.
Relief has a pipeline-in-waiting. From Relief web site:
Over the years, Relief Therapeutics has obtained a large number of patented indications for various peptides and proteins of natural origin. Although Relief is conscious that these experimental medicinal products might be beneficial to the patients, its limited resources prevent Relief from developing them further. These programs can be out-licensed to interested companies or organizations. Do not hesitate to contact us.
From the Relief Therapeutics website:
Aviptadil (Vasoactive Intestinal Peptide – VIP) is a biologically active and abundant human endogenous peptide ---
Aviptadil is a synthetic form of VIP, chemically identical to it, and therefore same half life.
Nice! Thanks!
C504 below, post # 26939, did a much better job of explaining the problem. He shows the picture of the page
Re your post #26934:
Welp I decided to take a stab at NeuroRX Revenues Including it's NRX-101 at a 20% market Share.. Using BARDA, NA Israel revenues only
and then COmbined the Two companies Revenues and here is what I got
(BAre in Mind I have no Idea the Share information on NeuroRX and Used Relief's FLoat and OS as A comparative in the NeuroRX share price)
Why am I getting a big fat MINUS sign instead of your revenue figures?
Hey Uncle Gee Gee, I noticed you always give a decent reply to someone who asks a halfway intelligent question. I appreciate that.
Shouldn't the EUA announcement come from the FDA?
I'm not Uncle Gee Gee, but to answer your question, Pilltracker looks like a compliance enhancement device for any medication, not specifically for RLF-100. They're probably using it in the inhaler trials to track inhaler compliance for accuracy of data.
One less competitor! BP too!
I think we are going to remain in this vortex with every news until people start seeing increasing revenues-the bottom line. Then we will REALLY take off!
Maybe it's a strategic decision to not pull the trigger on inhaler trials until EUA or full approval of IV version by the FDA. Maybe everything is ready to go, just waiting for the right signal.
Finally! We can now stop twiddling our thumbs!
I don't think they have Columbus Day in Switzerland.
How will VIP help gastric motility in diabetics if they already have high plasma VIP levels? They have lower numbers of VIP sensitive neurons than normal. Maybe their body is compensating by trying to produce more VIP?
COVAX and COVAXX are two different entities
Contrary to the current US love affair with India, it frequently infringes on drug patents. I'm afraid if they think aviptadil is critical for their needs, they will not honor any patents.
India has a highly developed pharmaceutical industry of its own and does not depend on Western pharmaceutical or chemical companies.
Indonesia is a better candidate as an aviptadil market, in addition to some others which have already been mentioned.
Your enthusiasm is very nice but misplaced in this case. Aviptadil will not work in preemies because the reason for their lack of surfactant is that they have not developed Type II alveolar cells.